Summary
Introduction In 2016 the World Health Organization (WHO) had adopted a global strategy to eliminate Hepatitis B (HBV) by 2030 through five core interventions, the first four were preventive while the fifth is the “cascade of care”, the continuum of services that persons with chronic HBV should receive as they progress from screening to diagnosis to treatment to chronic care. We determined the prevalence of the awareness and treatment of chronic HBV in Malaysia based on a large sample data from a screening campaign.
Methods A total of 10,436 subjects participated in the HBV screening campaign organized by the Hepatitis Free Pahang Malaysia (HFPM) in 2018 and 2019. All screen-positive subjects were recalled to undergo laboratory-based HBsAg and HBV DNA tests. Patients with confirmed chronic HBV were referred to local health services, while continued being monitored by HFPM.
Results We estimated 13.1% of Malaysian adults aged 20 or older with chronic HBV were aware of their HBV status, and of those only 0.7% had received prior anti-viral treatment, but among those with baseline HBV DNA level>20,000 IU/ml, 15.6% were subsequently treated. Tenofovir disoproxil fumarate was the only medicine used on all treated patients. The linkage to care post-screening was broken in substantial number of patients, only 108 (54%) subjects had returned to have their HBV DNA measured and only 115 (58%) patients had subsequently sought care and were on still follow-up.
Conclusion Few Malaysian adults with HBV were aware of their infection and even less received anti-viral therapy. Concerted public health efforts are urgently needed to improve HBV screening and care cascade in order to meet WHO’s targets for HBV elimination.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://hepatitisfreemsia.org.my/page.jsp?pageId=pResearch
Funding Statement
This study is funded by the Hepatitis Free Pahang Malaysia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Review & Ethics Committee (MREC), Ministry of Health Malaysia NMRR-16-2391-33614 (IIR) Protocol No : HR2017-01 Community screening and Prevalence of Hepatitis C and B in Pahang Malaysia based on low cost Point of Care Screening Tests (Community screening using low cost Point of Care tests, Assessment of disease activity using Nucleic Acid Tests and Outcome of patients treated with personally imported generic Anti-virals, for Chronic Hepatitis C and B in Malaysia)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
List of abbreviations
- CI
- Confidence interval
- HBV
- Hepatitis B virus
- HCC
- Hepatocellular carcinoma
- HCV
- Hepatitis C virus
- HFPM
- Hepatitis Free Pahang Malaysia
- MOH
- Ministry of Health Malaysia
- NGO
- Non-Governmental Organizations
- NHANES
- National Health Nutrition Examination Survey, US
- POCT
- Point of Care Tests
- SD
- Standard deviation
- WHO
- World Health Organization
- YLL
- Years of life lost